VivoSeq
Neurology

Dermatomyositis

46

Pipeline Programs↗

14

Active Trials↗

31

Companies Involved↗

Dermatomyositis is a moderately active landscape with 46 programs across 31 companies. The most active players are Biotech Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Sanofi. 3 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

11/100

Mech. Concentration

12/100

Completion Rate

65/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Biotech Pharmaceutical Co., Ltd.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 1K

Kyverna Therapeutics

1 program

Phase 1Amgen logo

Amgen

2 programs

Phase 2P

Priovant Therapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Acthar

Mallinckrodt

Immunosuppressive Agents

Medeor Therapeutics, Inc.

Lipid-Lowering Agents (artovastatin)

University of Sao Paulo

Drug Treatment

Biosense Webster, Inc.

Phase 15

Abatacept

Bristol-Myers Squibb

Itolizumab

Biotech Pharmaceutical Co., Ltd.

Immunoglobulin

Sanofi

KYV-101

Kyverna Therapeutics

MEDI-545

AstraZeneca

Phase 225

Methimazole

Viking Therapeutics, Inc.

Etanercept

Immunex

Infliximab

Organon and Co

Sodium Thiosulfate

Hope Pharmaceuticals

Ravulizumab

AstraZeneca

Phase 38

Ustekinumab

Johnson & Johnson

Baricitinib

Eli Lilly

Aldesleukin

Iovance Biotherapeutics, Inc.

Interleukin 2

Essen Biotech

GB-0998

Japan Blood Products Organization

Approved3

Tofacitinib

Prism Pharmaceuticals

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

JAK Inhibitor

Fred Hutchinson Cancer Center

Analysis

Modality Breakdown

74%

Small molecule

34 of 46 classified programs — the dominant modality here.

26%ALL OTHERSMonoclonal antibody715%Protein / enzyme49%Cell therapy12%

Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 100% of 50 pipeline programs.

Analysis

Trial Status

57

clinical trials

Completed24 · 42%
Terminated11 · 19%
Recruiting6 · 11%
Unknown status6 · 11%
Not yet recruiting3 · 5%
Active, not recruiting3 · 5%
Other4 · 7%

Clinical Trials

Trial Activity

57 trials

Baricitinib in Patients With Relapsing or naïve Dermatomyositis
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04972760·62 enrolled
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Recruiting·TThe Cleveland Clinic·Phase 2·NCT06857240·15 enrolled
Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation
Recruiting·PPeking Union Medical College Hospital·N/A·NCT07037472·100 enrolled
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Recruiting·SStanford University·Phase 1·NCT06298019·21 enrolled
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Recruiting·Pfizer logoPfizer·Phase 3·NCT05895786·318 enrolled
Studies in the Natural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory Myopathies
Recruiting·National Institute of Environmental Health Sciences (NIEHS)·N/A·NCT00017914·1,200 enrolled
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
Active, not recruiting·Argenx logoArgenx·Phase 2·NCT06284954·3 enrolled
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
Active, not recruiting·GGalapagos NV·Phase 2·NCT05695950·40 enrolled
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
Active, not recruiting·PPriovant Therapeutics, Inc.·Phase 3·NCT05437263·241 enrolled
Study of NM8074 in Patients with Dermatomyositis (DM)
Not yet recruiting·NNovelMed Therapeutics·Phase 2·NCT06887738·8 enrolled
Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis
Not yet recruiting·PPaean Biotechnology Inc.·Phase 2·NCT07122648·36 enrolled
Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
Not yet recruiting·—·Phase 2·NCT06568783·21 enrolled
3T Therapy in the Treatment of MDA5-positive Dermatomyositis
Enrolling by invitation·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT06438679·133 enrolled
Interleukin-2 on Active Dermatomyositis
Enrolling by invitation·PPeking University People's Hospital·Phase 3·NCT05495321·240 enrolled
A Study In Adults With Moderate To Severe Dermatomyositis
Completed·Pfizer logoPfizer·Phase 2·NCT03181893·75 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)